Comparison of whole gene and whole virus scrambled antigen approaches for DNA prime and fowlpox virus boost HIV type 1 vaccine regimens in macaques

AIDS Research and Human Retroviruses

Volumn 21, Issue 4, 2005, Pages 292-300

  Pamungkas, Joko ^a,b   De Rose, Róbert ^c   Iskandriati, Diah ^a   Noviana, Rachmitasari ^a   Paramastri, Yasmina ^a   Dale, C Jane ^c   Shoobridge, Maryanne ^d   Medveczky, C Jill ^d   Ramshaw, Ian A ^d   Thomson, Scott ^d   Kent, Stephen J ^c  

^a BOGOR AGRICULTURAL UNIVERSITY   (Indonesia)

^b UNIVERSITY OF INDONESIA   (Indonesia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Biology and Environment   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; DNA VACCINE; FOWLPOX VIRUS VACCINE; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POL PROTEIN; RECOMBINANT VACCINE; SCRAMBLED ANTIGEN VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CONSENSUS SEQUENCE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FOWLPOX VIRUS; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LYMPHOCYTE COUNT; MACACA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS GENE;

AIDS VACCINES; ANIMALS; CONSENSUS SEQUENCE; CROSS REACTIONS; FOWLPOX VIRUS; HIV ANTIBODIES; HIV ANTIGENS; HIV CORE PROTEIN P24; HIV INFECTIONS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; INTERFERON TYPE II; LYMPHOCYTE COUNT; MACACA NEMESTRINA; MODELS, ANIMAL; T-LYMPHOCYTES; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 20944447526     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.292     Document Type: Article

References (33)

1. Richman DD, Wrin T, Little SJ, and Petropoulos CJ: Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003;100:4144-4149.
2. Wei X, Decker JM, Wang S, et al.: Antibody neutralization and escape by HIV-1. Nature 2003;422:307-312.
3. Borrow P, Lewicki H, Wei X, et al.: Antiviral pressure exerted by HIV-1-specific CTLs during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3:205-211.
4. Moore CB, John M, James IR, Christiansen FT, Witt CS, and Mallal SA: Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002;296:1439-1443.
5. Levy DN, Aldrovandi GM, Kutsch O, and Shaw GM: Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci USA 2004;101:4204-4209.
6. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
7. Nabel GJ. Challenges and opportunities for development of an AIDS vaccine. Nature 2001;410:1002-1007.
8. + T cell responses associated with control of viremia. Science 1997;278:1447-1450.
9. Rosenberg ES, Altfeld M, Poon SH, et al.: Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-526.
10. Kent SJ, Zhao A, Best S, Chandler JD, Boyle DB, and Ramshaw IA: Enhanced T cell immunogenicity and protective efficacy from a HIV-1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpoxvirus. J Virol 1998;72:10180-10188.
11. Amara RR, Villinger F, Altman JD, et al.: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74.
12. Hanke T, Samuel RV, Blanchard TJ, et al.: Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999;73:7524-7532.
13. Allen TM, Vogel TU, Fuller DH, et al.: Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 2000;164:4968-4978.
14. Shiver JW, Fu T-M, Chen L, et al.: Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-335.
15. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, and Desrosiers RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:1938-1941.
16. Gauduin MC, Glickman RL, Ahmad S, Yilma T, and Johnson RP: Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and β-chemokine production. Proc Natl Acad Sci USA 1999;96:14031-14036.
17. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, and Ruprecht RM: Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995;267:1820-1825.
18. Kent SJ, Dale CJ, Preiss S, Mills J, Campagna D, and Purcell DJF: Vaccination with attenuated simian immunodeficiency virus by DNA inoculation. J Virol 2001;75:11930-11934.
19. Barouch DH, Santra S, Schmitz JE, et al.: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000;290:486-492.
20. + T cells by primary HIV-1 infection: potential mechanism of vaccine failure. J Immunol 1997;158:807-815.
21. Barouch DH, Kunstman J, Kuroda MJ, et al.: Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002;415:335-339.
22. Allen TM, O'Connor DH, Jing P, et al.: Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000;407:386-390.
23. Gaschen B, Taylor J, Yusim K, et al.: Diversity considerations in HIV-1 vaccine selection. Science 2002;296:2354-2360.
24. Korber B and Myers G: Los Alamos HIV Sequence Database, Los Alamos National Laboratory, Los Alamos, NM, 2002. Available at URL http://hiv-web.lanl. gov/content/hiv-db/mainpage.html.
25. Sandhu GS, Aleff RA, and Kline BC: Dual asymmetric PCR: One-step construction of synthetic genes. Biotechniques 1992;12:14-16.
26. Heine H and Boyle D: Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens. Arch Virol 1993;131:277-292.
27. Dale CJ, De Rose R, Wilson K, et al.: Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowl poxvirus vaccines co-expressing IFNγ or IL-12. Vaccine 2004;23:188-197.
28. Dale CJ, Liu XS, De Rose R, et al.: Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: Immunogenicity and protective efficacy in macaques. Virology 2002;301:176-187.
29. 28a. Dale CJ, De Rose R, Stratov I, et al.: Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus. J Virol 2004;78:13819-13828.
30. Amara RR, Smith JM, Staprans SI, et al.: Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol 2002;76:6138-6146.
31. Lynch JA, deSouza M, Robb MD, et al.: Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. J Infect Dis 1998;178:1040-1046.
32. Gloster SE, Newton P, Cornforth D, et al.: Association of strong virus-specific CD4 T cell responses with efficient natural control of primary HIV-1 infection. AIDS 2004;18:749-755.
33. Barouch DH, Pau MG, Custers JH, et al.: Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of per-existing anti-Ad5 immunity. J Immunol 2004;172:6290-6297.